Biologics
FDA Wants New Survival Trial Before Compass Files Tovecimig BLA
FDA has recommended that Compass Therapeutics conduct an additional clinical trial demonstrating an overall survival benefit before submitting a BLA for tovecimig and its use in previously treated, advanced biliary tract cancer patients, despite positive response rate and progression-free survival results from the Phase 2/3 COMPANION-002 study,